Navigation Links
Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytren's Contracture in E-poster at ASSH Meeting
Date:9/8/2011

nal recurrence rate for the 623 joints previously treated successfully with XIAFLEX was 34.8%. The study also tracks whether a joint successfully treated with XIAFLEX received any further medical intervention. Through year three of follow-up 93.1% of joints that were successfully treated with XIAFLEX did not receive any medical or surgical intervention. Of the 43 (6.9 %) successfully treated joints that received medical or surgical intervention through three years, 30 had surgery, seven received needle aponeurotomy (of which 2 subsequently received a third intervention), and six received XIAFLEX. XIAFLEX has been commercially available in the U.S. only since March 2010 with some interventions occurring in advance of its availability.

Through three years of follow-up, the adverse event profile of XIAFLEX treated joints demonstrated a local adverse event profile similar to previous first-line clinical studies and revealed no new long-term adverse events. One retreated patient reported a serious adverse event of a motor vehicle accident, which was considered unrelated to drug. Of the 74 serious adverse events reported through three years of follow-up, none were considered related to XIAFLEX and none occurred in the treated finger.

Recurrence with XIAFLEX as defined by greater than or equal to 30 degrees standard used in surgical literature

Although there is no standard methodology to measure recurrence, some literature (3,4) on surgical treatment does reference a definition of recurrence as a 30 degree worsening of contracture following an intervention. XIAFLEX recurrence was defined in the AUX-CC-860 clinical study as a 20 degree change in the presence of a palpable cord. In order to evaluate within the context of the existing surgical literature, the three year XIAFLEX data was examined using a criterion referenced in the literature. Specifically, for this post hoc analysis, the definition of recurrence was (a) a joint contracture that
'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Auxilium Pharmaceuticals Announces Positive Data from Commercial Patient Chart Review in E-posters at ASSH Meeting
2. Auxilium Pharmaceuticals, Inc. Announces Positive Top-Line Results from XIAFLEX® Multi-Cord Study
3. Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX®
4. Auxilium Pharmaceuticals Announces Investor Event to Occur at 2011 ASSH Meeting on September 9, 2011
5. Auxilium Pharmaceuticals to Present at the Stifel Nicolaus 2011 Healthcare Conference
6. Auxilium Pharmaceuticals, Inc. Announces Promotion of Dr. James P. Tursi to Chief Medical Officer
7. Auxilium Pharmaceuticals to Announce Second Quarter 2011 Results and Conduct Conference Call on Monday, August 1, 2011
8. Auxilium Pharmaceuticals Announces Results from Three Year CORDLESS Extension Study in Dupuytrens Contracture
9. Auxilium Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
10. Auxilium Pharmaceuticals to Present at the Deutsche Bank 36th Annual Health Care Conference
11. Auxilium Pharmaceuticals, Inc. Announces Launch of XIAPEX® in EU by Pfizer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, ... PTN), a biopharmaceutical company developing targeted, receptor-specific peptide ... unmet medical need and commercial potential, today announced ... of 2,050,000 shares of its common stock and ... its common stock.  Funds under the management of ...
(Date:12/24/2014)... Dec. 23, 2014 PuraMed BioScience®, Inc., (OTC ... (OTC) medicinal and healthcare products, announced it received the ... a hemp-based, advanced headache relief product, for planned distribution ... Colorado , Washington State ... With the MigraPure H Advanced headache relief gel formulation ...
(Date:12/24/2014)... , Dec. 23, 2014  Advanced Medical Isotope ... engaged primarily in the development of brachytherapy devices ... today announced that it has filed a ... Drug Administration ("FDA") for marketing clearance for its ... of the U.S. Food, Drug and Cosmetic Act ...
Breaking Medicine Technology:Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3
... Aug. 22, 2011 BioDelivery Sciences International, Inc. (Nasdaq: ... launch and availability of ONSOLIS (fentanyl buccal soluble film) ... (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO) ONSOLIS is approved in ... be marketed as BREAKYL) for the management of breakthrough ...
... the Food and Drug Administration (FDA) approved Seattle Genetics, ... – Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL). ... approved for Hodgkin lymphoma patients after failure of a ... ALCL patients after failure of at least one multi-agent ...
Cached Medicine Technology:BioDelivery Sciences Announces Commercial Launch of ONSOLIS in Canada 2BioDelivery Sciences Announces Commercial Launch of ONSOLIS in Canada 3The Leukemia & Lymphoma Society Available to Comment on FDA Approval of Seattle Genetics' Adcetris, First New Treatment for Hodgkin Lymphoma Since 1977 2
(Date:12/24/2014)... (PRWEB) December 24, 2014 New studies reveal ... to hearing loss related depression (March 6, 2014, JAMA Otolaryngology*). ... gradual hearing loss (about 50 percent according to recent polls) ... effect on how a person feels and relates to the ... overall improvements are also made by way of:, ...
(Date:12/24/2014)... The report “Stivarga (Colorectal Cancer) – ... current treatment landscape, unmet needs, current pipeline and commercial ... drug which is used in the treatment of colon ... is also prescribed to patients who suffer from advanced ... is a multi-kinase inhibitor and it blocks many enzymes ...
(Date:12/24/2014)... News) -- Hepatitis C infection does not contribute to mental ... Treatment advances have made it possible for people with ... thinking problems, mood swings and other types of mental impairment ... that long-term infections with other viruses -- a common problem ... of the prime suspects has been the hepatitis C virus, ...
(Date:12/24/2014)... 24, 2014 (HealthDay News) -- A lab technician with ... have been exposed to the Ebola virus in an ... up to a dozen other lab workers are being ... afternoon. The possible exposure occurred Monday when CDC ... of the potentially lethal virus to another CDC lab ...
(Date:12/24/2014)... Dr. Svetlana Gomer, MGS Tewksbury Dental, MGE Management ... US Marines on November 14, 2014 for the MGE ... for Tots Literacy Program. This year’s event raised ... audio books for the Toys for Tots Literacy Program ... represents another major strike in the battle being waged ...
Breaking Medicine News(10 mins):Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 2Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 3Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 4Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 5Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 6Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Hepatitis C Infection Isn't Related to HIV Brain Woes: Study 2Health News:CDC Monitors Lab Worker for Possible Ebola Exposure 2Health News:Dr. Svetlana Gomer, MGS Tewksbury Dental and Other Dentists Working With the U.S. Marines Strike Again In the Battle Against Illiteracy 2Health News:Dr. Svetlana Gomer, MGS Tewksbury Dental and Other Dentists Working With the U.S. Marines Strike Again In the Battle Against Illiteracy 3
... Researchers at the University of Toronto have identified a ... of neurons, which could enhance our understanding of how ... occur. U of T graduate student John Calarco, ... Centre for Cellular and Biomolecular Research, University of Toronto) ...
... mild depression more likely to suffer major episode later, ... Mildly depressed teenagers are more likely to have major ... new study suggests. , In 1983, researchers interviewed 755 ... and eating disorders, disruptive behaviors and substance abuse. , ...
... ... get Vaccinated , ... Washington, DC (Vocus) - The American Pharmacists Association (APhA) is recommending that ... vaccinated against influenza. Currently almost 80,000 pharmacists have been trained to administer immunizations and ...
... , , MINNEAPOLIS, Sept. ... at all 22 Target Clinic locations in Minnesota. The Centers ... against this potentially serious illness. , , ... available daily at Target Clinic locations during Clinic hours, including ...
... - Hard to Treat Diseases (the "Company") (HTDS.PK) ... Hope, has just finished (August 2009) the clinical ... NUTRIPROTEIN) in India. , This biological product is ... CNS in multiple ways, regulating and improving nerve ...
... could do the same, researchers say , FRIDAY, Sept. 4 ... animals may have a mechanism that allows them to jettison ... any age can do the same. , In fact, scientists ... go into deep storage. , "It,s fair to say that ...
Cached Medicine News:Health News:U of T researchers identify protein 2Health News:Depressed Teens Continue to Suffer 2Health News:Pharmacists Urge the Public to Begin Getting Immunized 2Health News:Pharmacists Urge the Public to Begin Getting Immunized 3Health News:Seasonal Flu Vaccinations Available Now at Target Clinics in Minnesota 2Health News:Seasonal Flu Vaccinations Available Now at Target Clinics in Minnesota 3Health News:Hard To Treat Diseases (HTDS) Completes Injection Clinical Trial 2Health News:Hard To Treat Diseases (HTDS) Completes Injection Clinical Trial 3Health News:Young Animals May Be Able to Erase Bad Memories 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: